London, 2 July 2015: Technavio, the independent tech-focused global research firm, has published a report on the autoimmune diseases drugs market in the US 2015-2019, which is expected to grow at a CAGR of 6.17% during the forecast period of 2014-2019.
The increasing prevalence of autoimmune diseases in the US region drives growth in the autoimmune drugs market. The introduction of new drugs that treat autoimmune diseases, coupled with government initiatives that improve people’s access to drugs will also propel market growth. Strategic alliances formed between different companies to develop effective drugs are also expected to escalate the demand for these drugs in the market.
“Many physicians are poorly trained in the area of autoimmune diseases. To overcome these drawbacks, a new specialty “Autoimmunologist” was planned to lead physicians from different disciplines within autoimmune triage centers. These community-based triage centers offer better services to patients,” says Faisal Ghaus, Vice President of Technavio.
“In tune with this, the US Congress introduced the Mary Colella Autoimmune Disease Awareness Act of 2012. This act strives to establish an autoimmune diseases committee that can coordinate government and private plans for autoimmune diseases.”
Key Market Drivers:
- Unmet Medical Needs.
- Increase in Prevalence of Autoimmune Diseases.
- Strong Pipeline Portfolio.
- Patient Assistance Programs.
Key Market Trends:
- Increased Public Awareness.
- Increase in R&D Expenditure.
- Strategic Alliances.
Key Market Vendors:
- AbbVie Inc.
- Amgen Inc.
- Biogen Inc.
- F. Hoffmann-La Roche Ltd.
- Janssen Pharmaceuticals Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges, and trends featuring data on product segmentations, vendor shares, growth rate by revenue, and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
